Compare Eli Lilly And Co (LLY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Repligen Corporation Common Stock — how do they compare? Eli Lilly And Co trades at $1,213.5 (market cap $1.04T), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Eli Lilly And Co is far larger — about 93.4× Repligen Corporation Common Stock's market cap, and Eli Lilly And Co pays a 0.59% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Repligen Corporation Common Stock for 0 Days on average.
| LLY | RGEN | |
|---|---|---|
Market Cap | $1.04T | $11.14B |
Volume | 1,843,375 | 1,259,263 |
Sector | Health | Health |
52-Week High | $1.28K | $194.57 |
52-Week Low | $799.57 | $102.87 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.09T | $11.02B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.
Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
